Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. Tsakok T, et al. Among authors: stocken d. JAMA Dermatol. 2019 Nov 1;155(11):1235-1243. doi: 10.1001/jamadermatol.2019.1783. JAMA Dermatol. 2019. PMID: 31532460 Free PMC article.
Doxycycline: a first-line treatment for bullous pemphigoid?
Grantham HJ, Stocken DD, Reynolds NJ. Grantham HJ, et al. Among authors: stocken dd. Lancet. 2017 Apr 22;389(10079):1586-1588. doi: 10.1016/S0140-6736(17)30549-4. Epub 2017 Mar 6. Lancet. 2017. PMID: 28279483 Free article. No abstract available.
Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.
Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; British Association of Dermatologists Biologic Interventions Register; Psoriasis Stratification to Optimise Relevant Therapy Study Groups. Thorneloe RJ, et al. J Invest Dermatol. 2018 Apr;138(4):785-794. doi: 10.1016/j.jid.2017.11.015. Epub 2017 Nov 26. J Invest Dermatol. 2018. PMID: 29183731 Free PMC article.
An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema.
Brass D, Fouweather T, Stocken DD, Macdonald C, Wilkinson J, Lloyd J, Farr PM, Reynolds NJ, Hampton PJ. Brass D, et al. Among authors: stocken dd. Br J Dermatol. 2018 Jul;179(1):63-71. doi: 10.1111/bjd.16238. Epub 2018 Mar 14. Br J Dermatol. 2018. PMID: 29235664 Free article. Clinical Trial.
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N. Danilenko M, et al. Among authors: stocken dd. JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610. JAMA Dermatol. 2018. PMID: 29955768 Free PMC article. Clinical Trial.
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.
Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group; PSORT consortium. Wilkinson N, et al. Among authors: stocken d. J Invest Dermatol. 2019 Jan;139(1):115-123. doi: 10.1016/j.jid.2018.07.028. Epub 2018 Aug 18. J Invest Dermatol. 2019. PMID: 30130616 Free PMC article.
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.
Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group. Warren RB, et al. Among authors: stocken d. Br J Dermatol. 2019 May;180(5):1069-1076. doi: 10.1111/bjd.16776. Epub 2018 Aug 28. Br J Dermatol. 2019. PMID: 30155885 Free PMC article.
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN; BADBIR Study Group; BSTOP Study Group; PSORT Consortium. Dand N, et al. J Allergy Clin Immunol. 2019 Jun;143(6):2120-2130. doi: 10.1016/j.jaci.2018.11.038. Epub 2018 Dec 20. J Allergy Clin Immunol. 2019. PMID: 30578879 Free article.
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, Smith CH; BADBIR study group and the PSORT consortium. Mahil SK, et al. Among authors: stocken d. Br J Dermatol. 2020 May;182(5):1158-1166. doi: 10.1111/bjd.18333. Epub 2019 Sep 10. Br J Dermatol. 2020. PMID: 31286471 Free PMC article.
125 results